AI in Clinical Trials Moved From Pilot to Production — And Most Sponsors Aren’t Ready
A VP of Clinical Operations spent $2.4 million on an AI platform for enrollment forecasting, site performance prediction, and protocol risk identification. The software was deployed nine months ago.
Nine months later, her team still uses Excel for enrollment forecasts.
This isn’t a technology problem. It’s an implementation problem. And it’s costing sponsors hundreds of millions in wasted spend on tools they can’t operationalize.
2026 Is the Implementation Year, Not the Pilot Year
The AI landscape in clinical trials shifted between 2023 and 2025. From proof-of-concept to production deployment. AI is now embedded across feasibility studies, recruitment strategy, data quality monitoring, safety signal detection, and protocol optimization.
But there’s a gap. A massive gap. The gap between buying AI and operationalizing AI is the biggest source of wasted technology spend in clinical development.
Sponsors are buying AI tools. They’re not changing their organizations to use them.
The VP who spent $2.4 million on an AI platform has the right tool. Her team doesn’t have the right workflow. They don’t have the right dashboards. They don’t have the right data pipelines. And most critically, they don’t have organizational permission to act on the AI’s recommendations without approval from three levels of management.
So the Excel lives on. The AI sits idle. And the $2.4 million disappears into the cost of doing business.
Three Things Successful Sponsors Share
This is where execution discipline matters. Sponsors who are successfully deploying AI in 2026 share three characteristics:
First, they embed AI into existing tools, not into new dashboards. They don’t ask teams to learn a new interface. They integrate AI into the EDC, the CTMS, the patient recruitment platform. The data scientist works in the background. The operational team works in familiar tools.
Example: Instead of deploying a separate “AI enrollment forecasting platform,” integrate enrollment forecasting models directly into the site performance dashboard that clinical monitors already use daily. No new interface. No new training. Same daily workflow, better data.
Second, they started with ONE use case and proved ROI before scaling. Not a platform deployment with 47 different AI applications. Pick one problem: enrollment forecasting, data quality, or safety signal detection. Build the data infrastructure. Deploy. Measure. Prove ROI. Then expand.
This takes discipline because the AI vendor wants to sell you the whole platform and the CXO wants to believe AI will transform everything. The reality is that operational change happens one workflow at a time.
Third, they invested 60% in data infrastructure and 40% in AI. Most sponsors reverse this ratio. They buy expensive AI tools and hope the data will cooperate. It won’t.
Data infrastructure means: clean data pipelines from your EDC to your data lake, validated data quality at source, automated data standardization, real-time data governance, and accessible data warehousing. If you don’t have this, AI is predicting noise.
Successful deployments spend 18-24 months building data infrastructure before they expect the AI to deliver value.
FDA Wants Traceable, Explainable Logic
There’s also a regulatory dimension that most sponsors are underestimating. The FDA is becoming increasingly vocal about AI’s role in submissions. They want traceable logic, not black boxes.
If you’re using AI to predict dropout risk and deciding to intensify monitoring for high-risk sites, the FDA will ask: What’s the algorithm? What data inputs? How was it trained? Can you show me the decision tree?
You can’t answer that with a vendor’s proprietary black box. You need to own the logic, understand the inputs, and be able to explain the recommendations.
This means you can’t just buy and deploy. You need to validate. You need to document. You need to build audit trails. This is part of your regulatory submission strategy, not your operational technology strategy.
Organizations that are treating AI as a regulatory component of their trial design (and documenting it accordingly) are building competitive advantage. Organizations that are treating it as an operational tool they’ll figure out later will hit regulatory complications at submission.
The 18-Month Window
2026-2027 is the operationalization window. AI for clinical trials moved from experimental to expected sometime between 2025 and 2026. By 2028, AI-supported submissions will be the norm, not the outlier. Sponsors without operational AI deployment by then will be behind.
This doesn’t mean you need to deploy everything. It means you need to have moved beyond pilot, proven ROI on one use case, and built organizational readiness for the next wave.
The Strategic Truth
The AI was always ready. The organization needed to catch up.
Vendors have had production-grade AI for clinical trials since 2023. The bottleneck isn’t technology. It’s organizational change management. It’s data infrastructure. It’s regulatory thinking.
The sponsors who deployed AI successfully in 2025 didn’t have smarter people. They had different disciplines. They embedded AI into existing tools. They proved one use case. They invested in data infrastructure. They thought about regulatory implications.
That’s not innovation. That’s execution.
And execution is what separates the 15% of sponsors who are operationalizing AI in 2026 from the 85% who are still hoping to deploy it “eventually.”
